About_Suzhou Womei Biology Co.,Ltd

Company Profile

Suzhou Womei Biology Co., Ltd. (referred to as "Womei Biology") is a one-stop solution provider in the biomanufacturing industry. Its products include personalized media, bioreactors, immune adjuvants, biochemical reagents, etc. Womei Biology is a core supplier of upstream and downstream bioprocesses, and also provides formulation production, process optimization, process validation, technical support, and ancillary services for the biopharmaceutical industry.

The founding team of Womei Biology consists of outstanding graduates from the State Key Laboratory of Bioreactor Engineering at East China University of Science and Technology. They inherit over three decades of technical expertise and application experience accumulated by the laboratory in animal cell culture process engineering and bioreactor engineering. Building on this talent foundation, the company has also attracted high-level professionals from institutions such as Shanghai Jiao Tong University, Fudan University, Sichuan Agricultural University, and multinational corporations like Bosch in Germany. To date, the company has established an R&D team of over 150 members, including 15 Ph.D. holders and 60 master’s degree holders. With nearly 10,000 square meters of R&D facilities and cumulative R&D investment exceeding 200 million RMB, the company is well-equipped for innovation.

As a one-stop service provider in the biopharmaceutical industry, Womei Biology has established the No. 1 production base in Zhangjiagang, R&D centers in Shanghai, Suzhou, and the WorldTex R&D Center in Shanghai and Wuhan. These efforts drive comprehensive upgrades in process development, quality systems, management systems, and production capacity. The No. 2 production base in Zhangjiagang comprises four workshops, covering nearly 10,000 square meters, with a maximum single-batch capacity exceeding 100,000 liters.

Relying on a strong R&D team, Womei Biology has preliminarily established a layout for upstream and downstream bioprocessing solutions, aiming to become a high-tech upstream product and service enterprise in China's biopharmaceutical industry. In the future, the company strives to develop into a comprehensive service provider offering complete solutions for the domestic biopharmaceutical sector. It is committed to providing high-quality technical services to China's antibody, vaccine, and cell therapy enterprises, supporting the global expansion of innovative biopharmaceutical products such as antibodies, vaccines, and cell therapies from China.

Milestone

Development Path

Suzhou Womei Biology Co.,Ltd ( acronyms：Womei Biology )

2010

1.To establish Shanghai MIDI Biotechnology Co. , Ltd；

2.To develop the serum-free culture medium for insect cells in China;

3.To sign a cooperation agreement with the National Center for Biochemical Engineering and technology (Shanghai) to jointly carry out technical services;

2012

1.Suzhou Wome Biological Co. , Ltd. was established;

2.Signed and completed technical service projects with a number of large biological products enterprises;

3.The domestic market share of insect cell culture media products increased significantly;

2014

1.BHK serum-free medium was used in the production of foot-and-mouth disease on a large scale to replace the imported products;

2.Animal vaccines of several genetic engineering subunits were completed and many clinical cases were declared;

2016

1.The establishment of the Bioreactor Product Division；

2.The official establishment of the Shanghai Songjiang R & D Center (genetic engineering and cell engineering) ；

3.The establishment of Suzhou Sinobiology, focusing on the new veterinary drug CRO business;

2018

1.The market share of cell culture media is growing rapidly in China;

2.Strategic cooperation agreements have been signed with enterprises in the industry, such as Jinyubiao, Ripp Biological, Qilu animal protection, etc. ;

3.East China University of technology to establish the animal vaccine adjuvant products division;

2020

1.Womeibio was established and settled in Fenghuang Town, Zhangjiagang, integrating the original media, reactor, adjuvant and other business;

2.Expansion of Shanghai R & D Center, it will form three core laboratories of genetic engineering and diagnosis, cell engineering and microbial purification, with a total area of 2000 square meters；

3.More than 100 utility model patents for authorized invention of genetic engineering animal vaccine;

The sales revenue of the enterprise exceeds 100 million yuan

2022

1.Construction of a new production base in Zhangjiagang；

2.Merger of wome with sinobom to further consolidate its business and strengthen its vaccine CRO business；

3.Construction of a research and development centre in Shanghai；

4.Establishment of a holding company, Nantong WorldTex, facheng haoxin (zhichun technology 603690.SH) investment, focusing on high-end Bioreactor；

5.The establishment of the East China University of Science and Technology Bioreactor Process Control and intelligent manufacturing technology transfer centre;

2023

1.Leaders of the standing committee of the CPC Zhangjiagang Municipal Committee visited the WOMEI biological production base;

2.The IPO of the science and Technology Innovation Board was launched and signed;

3.The agreement was signed to enter the flying bio-pharmaceutical industry park in Zhangjiagang;

2024

(1) Shanghai R&D Center & Global Business Headquarters Completed;

(2) Synthetic Biology CDMO Factory Project Signed;

(3) Overseas Business Division Thriving;

(4) Synthetic Biology Industrial Division Growing Rapidly;

2025

(1) The Zhangjiagang Phase II Quality Control Center Completed;

(2) WorldTex (Shanghai)-Jinshan Factory Completed;

(3) Unveiling of the “Womei Lecture Hall" at the School of Biotechnology, East China University of Science and Technology;

(4) Approved as a Five-Star "Biomanufacturing Pilot Capability Construction Platform" by the Ministry of Industry and Information Technology;

(5) Approved as a "High-Performance Bioreactor" Initiative Undertaker by the Ministry of Industry and Information Technology, Undertaking 6 National-Level Key Projects;